In an increasingly crowded market, where performance is only one of many factors for an LP to consider, are GPs successfully differentiating themselves from their peers when it comes to positioning and pitching?

In an increasingly crowded market, where performance is only one of many factors for an LP to consider, are GPs successfully differentiating themselves from their peers when it comes to positioning and pitching?
Atlas Venture is a Cambridge, MA based early stage venture capital firm focused on biotech. The firm invests exclusively in the therapeutics space within biotech where they are focused on venture creation. We spoke with Kristen Margeson, senior director of IR and marketing at Atlas to learn more about how the firm successfully uses TopQ in their fundraising and investor relations efforts.
In late August, eVestment Private Markets hosted a virtual panel with two LP investors about adapting to digital due diligence. During the conversation, one of the investors had this to say about the remote environment the industry is now operating in, “What’s been a challenge is not having informal interactions, not having AGMs where you can have those longer informal conversations with your managers, and your peers – the exchange of ideas is not as strong at the moment.”
LPs are increasingly focused on the quantitative side of GP value creation during due diligence – looking to validate claims and understand portfolio strategies with data. But are GPs using quantitative data to their advantage to evidence their value-add strengths in their pitch decks and presentations, to go beyond mere claims?
Members of the private markets teams from Aberdeen Standard Investments and APG Asset Management recently joined eVestment Private Markets for a discussion about how their due diligence processes have changed in the last few months, and the challenges and opportunities the crisis has presented.
Graeme Faulds, Director of Product at eVestment Private Markets sits down with Nasdaq’s Jill Malandrino to discuss how the COVID-19 pandemic has affected private equity fundraising in 2020. Here are three key takeaways from the segment.